Sonnet BioTherapeutics shares are trading higher after the company's Phase 1b/2a clinical trial of SON-080 was cleared to proceed to Phase 2 after review by an independent DSMB.
Portfolio Pulse from Benzinga Newsdesk
Sonnet BioTherapeutics' shares surged following the clearance to proceed to Phase 2 for its SON-080 clinical trial after an independent DSMB review.
March 11, 2024 | 11:47 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Sonnet BioTherapeutics' stock price is likely to experience a short-term increase following the positive news about its SON-080 clinical trial moving to Phase 2.
The advancement of SON-080 to Phase 2 is a critical milestone for Sonnet BioTherapeutics, indicating potential efficacy and safety of the treatment. Such positive developments typically lead to increased investor confidence and can drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100